(Q51557839)

7 April 2018

title

Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. (English)

1 reference

7 April 2018

1 reference

1

1 reference

7 April 2018

author name string

Eschwège E

2

1 reference

7 April 2018

Grandmottet P

3

1 reference

7 April 2018

Isnard F

4

1 reference

7 April 2018

Cohen JM

5

1 reference

7 April 2018

Bensoussan JL

6

1 reference

7 April 2018

Berche H

7

1 reference

7 April 2018

Chapiro O

8

1 reference

7 April 2018

André P

9

1 reference

7 April 2018

Vague P

10

1 reference

7 April 2018

Juhan-Vague I

11

1 reference

7 April 2018

Bard JM

12

1 reference

7 April 2018

Safar M

13

1 reference

7 April 2018

publication date

1 January 2000

1 reference

7 April 2018

Diabetes - Metabolism: Research and Reviews

published in

1 reference

7 April 2018

volume

16

1 reference

7 April 2018

issue

1

1 reference

7 April 2018

page(s)

2-7

1 reference

7 April 2018

Regional obesity and risk of cardiovascular disease; the Framingham Study

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

A comparison of metformin versus guar in combination with sulphonylureas in the treatment of non insulin dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Prospective Study of Serum -Glutamyltransferase and Risk of NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

Cholesterol Lowering Effect of Metformin in Combined Hyperlipidemia: Placebo Controlled Double Blind Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291520-7560%28200001%2F02%2916%3A1%3C2%3A%3AAID-DMRR75%3E3.0.CO%3B2-G

10.1002/(SICI)1520-7560(200001/02)16:1<2::AID-DMRR75>3.0.CO;2-G

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

10707032

1 reference

7 April 2018